Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and small-molecule treatments for inherited retinal diseases (IRDs). The company's pipeline includes OPGx-LCA5, currently in Phase 1/2 clinical trials for LCA5-associated IRD, and OPGx-BEST1 for BEST1-associated retinal disease. Additional programs in preclinical development target retinitis pigmentosa, retinal dystrophy, and other IRD indications caused by mutations in specific genes including RHO, RDH12, MERTK, NMNAT1, and CNGB1. Most candidates employ AAV vector-based gene augmentation or restoration approaches.
Beyond its IRD focus, Opus Genetics is developing Phentolamine Ophthalmic Solution for mydriasis reversal and potential presbyopia treatment, as well as APX3330, a small-molecule Ref-1 inhibitor for diabetic retinopathy. The company operates with a small team of 18 full-time employees based in Durham, North Carolina. Opus Genetics was incorporated in Delaware and trades on the Nasdaq under the ticker IRD. The company was founded in 2018 and was formerly known as Ocuphire Pharma, Inc.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.15 | $-2.15 | -367.4% | |
| 2023 | $-0.46 | $-0.46 | -152.9% | |
| 2022 | $0.87 | $0.90 | +122.8% | |
| 2021 | $-3.82 | $-3.82 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | $-0.12 | $-0.12 | +0.0% | |
| 2017 | $-0.12 | $-0.12 | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001140361-25-011410 | SEC ↗ |
| 2023-12-31 | 2024-03-08 | 0001140361-24-012399 | SEC ↗ |
| 2022-12-31 | 2023-03-30 | 0001140361-23-014868 | SEC ↗ |
| 2021-12-31 | 2022-03-24 | 0001140361-22-011015 | SEC ↗ |
| 2020-12-31 | 2021-03-11 | 0001140361-21-008099 | SEC ↗ |
| 2019-12-31 | 2020-02-21 | 0001140361-20-003785 | SEC ↗ |
| 2018-12-31 | 2019-03-07 | 0001140361-19-004539 | SEC ↗ |
| 2017-12-31 | 2018-03-09 | 0001140361-18-012817 | SEC ↗ |
| 2016-12-31 | 2017-02-24 | 0001140361-17-009132 | SEC ↗ |
| 2015-12-31 | 2016-03-14 | 0001140361-16-057543 | SEC ↗ |
| 2014-12-31 | 2015-03-16 | 0001140361-15-011969 | SEC ↗ |
| 2013-12-31 | 2014-03-21 | 0001140361-14-013828 | SEC ↗ |
| 2012-12-31 | 2013-03-22 | 0001140361-13-013730 | SEC ↗ |
| 2011-12-31 | 2012-03-16 | 0001140361-12-016054 | SEC ↗ |
| 2010-12-31 | 2011-03-16 | 0001140361-11-017219 | SEC ↗ |
| 2009-12-31 | 2010-03-31 | 0001140361-10-014461 | SEC ↗ |
| 2008-12-31 | 2009-03-16 | 0001140361-09-007160 | SEC ↗ |